Oddo BHF Asset Management Sas acquired a new position in shares of CureVac N.V. (NASDAQ:CVAC – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 650,557 shares of the company’s stock, valued at approximately $2,941,000. Oddo BHF Asset Management Sas owned 0.29% of CureVac at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. L2 Asset Management LLC grew its holdings in CureVac by 38.5% during the fourth quarter. L2 Asset Management LLC now owns 19,756 shares of the company’s stock worth $89,000 after acquiring an additional 5,495 shares during the period. Jane Street Group LLC lifted its position in shares of CureVac by 175.2% during the 4th quarter. Jane Street Group LLC now owns 203,665 shares of the company’s stock valued at $866,000 after acquiring an additional 129,670 shares during the period. Leonteq Securities AG acquired a new stake in shares of CureVac during the 4th quarter valued at approximately $127,000. SG Americas Securities LLC acquired a new stake in shares of CureVac during the 4th quarter valued at approximately $79,000. Finally, Qube Research & Technologies Ltd lifted its position in shares of CureVac by 44.9% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,712,737 shares of the company’s stock valued at $9,232,000 after acquiring an additional 530,686 shares during the period. Institutional investors and hedge funds own 17.26% of the company’s stock.
CureVac Price Performance
CVAC stock opened at $4.66 on Wednesday. The firm has a 50 day moving average of $4.66 and a 200-day moving average of $4.68. CureVac N.V. has a 12-month low of $3.13 and a 12-month high of $5.72. The company has a current ratio of 3.70, a quick ratio of 3.69 and a debt-to-equity ratio of 0.03. The company has a market cap of $1.05 billion, a price-to-earnings ratio of 6.47 and a beta of 1.77.
CureVac Profile
CureVac N.V. is a clinical-stage biopharmaceutical company that specializes in the research, development and commercialization of messenger RNA (mRNA)-based medicines and vaccines. Leveraging its proprietary mRNA platform, the company seeks to harness the body’s natural protein production processes to address a range of diseases, with particular emphasis on prophylactic vaccines for infectious diseases as well as therapeutic candidates in oncology. CureVac’s technology is designed to deliver optimized mRNA sequences for in vivo expression, aiming to improve stability, translational efficiency and immunogenicity compared with conventional approaches.
Founded in 2000 and headquartered in Tübingen, Germany, CureVac has built a pipeline spanning early- to late-stage clinical programs.
Further Reading
- Five stocks we like better than CureVac
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Want to see what other hedge funds are holding CVAC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CureVac N.V. (NASDAQ:CVAC – Free Report).
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.
